Autism-linked CHD gene expression patterns during development predict multi-organ disease phenotypes

Sahrunizam Kasah*, Christopher Oddy* & M. Albert Basson^

Centre for Craniofacial and Regenerative Biology, King's College London, Floor 27, Guy's Hospital Tower Wing, London SE1 9RT, UK and MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK.

*Joint first authors

^Correspondence:

Dr. M.A. Basson

Centre for Craniofacial and Regenerative Biology King's College London

Floor 27, Guy's Hospital Tower Wing

London SE1 9RT

UK

Tel: +44-207 188 1804

email: albert.basson@kcl.ac.uk

Keywords: CHD2, CHD7, CHD8, expression, mouse, autism, embryo, development, organogenesis

Short title: CHD gene expression during mouse development
Abstract

Recent large-scale exome sequencing studies have identified mutations in several members of the CHD (Chromodomain Helicase DNA-binding protein) gene family in neurodevelopmental disorders. Mutations in the CHD2 gene have been linked to developmental delay, intellectual disability, autism and seizures, CHD8 mutations to autism and intellectual disability, whereas haploinsufficiency of CHD7 is associated with executive dysfunction and intellectual disability. In addition to these neurodevelopmental features, a wide range of other developmental defects are associated with mutants of these genes, especially with regards to CHD7 haploinsufficiency, which is the primary cause of CHARGE syndrome. Whilst the developmental expression of CHD7 has been reported previously, limited information on the expression of CHD2 and CHD8 during development is available. Here we compare the expression patterns of all three genes during mouse development directly. We find high, widespread expression of these genes at early stages of development that gradually becomes restricted during later developmental stages. Chd2 and Chd8 are widely expressed in the developing central nervous system (CNS) at all stages of development, with moderate expression remaining in the neocortex, hippocampus, olfactory bulb and cerebellum of the postnatal brain. Similarly, Chd7 expression is seen throughout the CNS during late embryogenesis and early postnatal development, with strong enrichment in the cerebellum, but displays low expression in the cortex and neurogenic niches in early life. In addition to expression in the brain, novel sites of Chd2 and Chd8 expression are reported throughout the developing mouse. These findings suggest additional roles for these genes in organogenesis and predict that mutation of these genes may predispose individuals to a range of other, non-neurological developmental defects.
Introduction

Chromatin remodelling factors have emerged as key regulators of gene expression and are often mutated in human disease (Iwase et al, 2018; Hendrich and Bickmore, 2001; Ronan, Wu & Crabtree et al, 2013). Mammalian chromatin remodelling factors can be subdivided into four families: SWI/SNF (mating type Switching/Sucrose Non-Fermenting), ISWI (Imitation Switch), INO80 (Inositol requiring 80) and CHD (Chromdomain Helicase DNA-binding protein) (Ho and Crabtree, 2010).

The CHD gene family consists of nine genes (CHD1-CHD9). The encoded proteins utilise the energy from ATP hydrolysis to alter nucleosome positioning, thereby causing local changes in the structure of the chromatin (Marfella & Imbalzano, 2007). CHD1 and CHD2, which belong to CHD1-2 subfamily, are characterised by the presence of tandem chromodomains and a Snf2 helicase domain – both motifs common to all CHD proteins – in addition to DNA-binding domains at the C-terminus (Marfella & Imbalzano, 2007; Liu, Ferreria & Yusufzai, 2015). CHD3 and CHD4 are structurally similar but each contain a PHD (Plant Homeo Domain) Zn-finger-like domain rather than a DNA binding region, forming the second subfamily (Marfella & Imbalzano, 2007). Alongside signature sequence motifs of the CHD family, members of the CHD5-9 subfamily contain a DNA binding region alongside various other C-terminal sequences that alter their function (Marfella & Imbalzano, 2007). The present study focuses on the spatiotemporal pattern of expression of CHD2, CHD7 and CHD8.

The ATP-dependent activity of CHD2 leads to assembly of chromatin into periodic nucleosome arrays by deposition of various histone proteins, thereby modifying the expression and structure of target sites (Liu, Ferreria & Yusufzai, 2015; Luijsterburg et al., 2016). Functionally, CHD2 has been reported to maintain pluripotency of stem cells, influence cell fate during myogenesis and interneuron development and facilitate DNA repair through interaction with histone variant H3.3 (Harada et al, 2012; Luijsterburg et al., 2016; Meganathan et al, 2017; Rajagopalan, Nepa & Venkatachalam et al., 2012; Semba et al, 2017).
De novo loss-of-function mutations in CHD2 have been reported in Autism Spectrum Disorder (ASD) patients alongside developmental delay, intellectual disability, increased risk of epileptic seizures and additional behavioural problems (Allen et al, 2013; Chérnier et al, 2014; Lebrun et al, 2017; O’Roak et al, 2014; Pinto et al, 2016). The association between CHD2 haploinsufficiency and epileptic encephalopathy, or Lennox-Gastaut or Dravet syndrome, is also well-established and variants of CHD2 are recognised risk factors for photosensitivity in epilepsy (Carvill et al, 2013; Galizia et al, 2015; Lund et al, 2014; Suls et al, 2013). CHD2 mutations are commonly identified in patients with chronic lymphocytic leukaemia, frequently in conjunction with alterations in functional pathways associated with brain development (Rodriguez et al, 2015).

Homozygous Chd2 mutant mice die around birth due to unknown causes (Marfella et al, 2006). Heterozygous mice exhibited reduced growth and viability and range of phenotypic abnormalities which include extramedullary haematopoiesis, susceptibility to lymphomas, cardiomyopathy, liver inflammation, glomerulopathy and various other renal defects (Marfella et al, 2006; Marfella et al, 2008; Nagarajan et al, 2009; Rajagopalan, Nepa & Venkatachalam et al., 2012). More recently Chd2 knockdown has been demonstrated to decrease Pax6⁺ radial glial cell numbers, a cell type in which it is highly expressed, and to promote neuronal and intermediate progenitor production, implying an important balancing role for CHD2 in progenitor renewal and cortical development (Shen et al, 2015). At present limited expression data for Chd2 is available. Quantitative analyses of Chd2 in the adult mouse demonstrate that Chd2 is widely expressed by a multitude of functional tissue groups including the heart, brain, lungs, thymus, lymphoid tissue and skeletal muscle (Marfella et al, 2006; Nagarajan et al, 2009). Macroscopic analysis of whole embryos stained for Chd2 showed expression in the developing heart, forebrain, eye, dorsal facial region and limbs between E10.5 and E15.5 (Kulkarni et al, 2008). These data show that Chd2 expression is apparent in many tissues during development and in the adult mouse although a true spatiotemporal pattern of expression is yet to be defined.
CHD7 is thought to maintain an open chromatin conformation at putative regulatory elements (Feng et al, 2017; Whittaker et al, 2017b). CHD7 facilitates neural stem cell (NSC) multipotency in the developing brain and quiescence in the adult as both differentiation potential and stem cell depletion rates are correlated with the levels of CHD7 (Feng et al, 2015; Fujita, Ogawa & Ito, 2016; Jones et al, 2015; Yamamoto et al, 2018). As well as maintaining multipotency, CHD7 has also been shown to directly control lineage identity in NSCs through coordination of transcription factors in the neural crest (Chai et al, 2018). In a similar vein, CHD7 is required for the formation of migratory neural crest cells and, accordingly, induced pluripotent stem cells (iPSCs) derived from patients with CHD7 mutations exhibit defective delamination, migration and motility (Bajpai et al, 2010; Prasad et al, 2012; Okuno et al, 2017). Finally, CHD7 has been shown to have multiple roles in cerebellar development; consistent with the observation that individuals harbouring CHD7 mutations may exhibit vermis hypoplasia (Yu et al, 2013; Whittaker et al, 2017a; Whittaker et al, 2017b; Donovan et al, 2017).

Haploinsufficiency of the CHD7 gene is the major cause of CHARGE syndrome (Coloboma of the eye, Heart defects, Atrresia of the choanae, Retardation of growth and/or development, Genitalia and/or urinary abnormalities and Ear abnormalities and deafness) and mutations have also been reported in patients with Kallmann syndrome (Jongmans et al, 2009; Kim et al, 2008). Some of the CHD7 mutations in patients with CHARGE syndrome have been shown to result in defective nucleosome remodelling activity in-vitro, directly linking chromatin remodelling defects with disease (Bouazoune and Kingston, 2012). Chd7−/− embryos do not survive beyond E11, indicating early requirements for this gene during embryonic development, whereas heterozygotes exhibit features similar to those associated with CHARGE syndrome (Bosman et al, 2005; Hurd et al, 2007). Akin to Chd2, Chd7 expression during development is not limited to one tissue type. Chd7 has been shown to be expressed in the developing eye, inner ear, olfactory epithelium, dorsal root ganglia, lung, kidneys, gut and throughout the neural ectoderm, including the neural crest (Aramaki et al, 2007; Bosman et al, 2005; Engelen et al, 2011; Fujita et al, 2014; Fujita Ogawa & Ito, 2016; Gage, Hurd & Martin, 2015; Hurd et al, 2007). More recently, preserved expression of Chd7 has been seen in the adult cerebellum (Whittaker et al, 2017a).

Recurrent de novo mutations in CHD8 have been linked to ASD. A significant body of literature, including case reports and large exome sequencing studies, have identified CHD8 mutations in individuals with ASD (Bernier et al, 2014; Neale et al, 2012; Merner et al, 2016; O’Roak et al, 2012; Sanders et al, 2012; Stolerman et al, 2016; Talkowski et al, 2012; Wang et al, 2016; Wilkinson et al, 2015; Zahir et al, 2007). It is one of the highest confidence risk genes for autism identified to date. ASD is highly heterogeneous but can be identified by a repertoire of behavioural features in patients: social impairment, communication impairment, repetitive behaviours and sometimes accompanied by an array of other conditions such as epilepsy, dyslexia, dyspraxia and attention deficit hyperactivity disorder (ADHD) (Brieber et al, 2007; Canitano, 2007; Dziuk et al, 2007; Helbig et al, 2009; Leyfer et al, 2006; Taurines et al, 2012). The effects of CHD8 mutation may also manifest as characteristic physical features including macrocephaly, facial dysmorphia and gastrointestinal disturbance, perhaps defining CHD8-related ASD as a distinct subtype (Bernier et al, 2014).

CHD8 is recruited to promoters of highly expressed genes in NSCs and reduced expression of CHD8 in mouse and human cells has been shown to precipitate dysregulation of ASD related genes and alter cortical neurogenesis (Cotney et al, 2015; Durak et al, 2016; Sugathan et al, 2014; Wang et al, 2015; Wilkinson et al, 2015). In Chd8+/- mice behavioural changes have been documented alongside characteristic neurodevelopmental changes pertaining to altered neurogenesis and long-range connectivity, brain overgrowth and craniofacial anomalies (Gompers et al, 2017;
Katayama et al, 2016; Platt et al, 2017; Suetterlin et al, 2018). \(Chd8^{-/-}\) embryos die by E7.5 of development. The early embryonic lethality associated with CHD8 loss has been proposed to be caused by aberrant p53-mediated apoptosis as a consequence of loss of CHD8-mediated repression of p53 target genes (Nishiyama et al, 2004). As the mutants do not survive, the developmental roles after E7.5 are not known. The expression pattern of \(Chd8\) has been described between E7.5 and E10.5 in the mouse using a CHD8s/Duplin antisense riboprobe (Nishiyama et al, 2004). Whole embryo analysis showed expression predominantly in the brain, face and limb buds. Since, microarray data has been used to quantify the level of \(Chd8\) expression in developing mouse, macaque and human brains.

A regional expression heatmap showed widespread expression, highest in the early prenatal period (Bernier et al, 2014). Platt et al (2017) demonstrated a similar temporal pattern of quantitative expression in the mouse brain and further showed that \(Chd8\) is expressed in almost all neuronal populations. Despite these insights, no study to date has characterised the macroscopic expression pattern of \(Chd8\) in all tissues of the developing mouse from mid-gestation and through early life. Given the strong association of CHD8 mutations with ASD and other physical abnormalities, determining a comprehensive spatiotemporal expression pattern of CHD8 during development is of great interest.

In the present study, we investigated the spatiotemporal patterns of three CHD genes with strong evidence for important functions in brain development and neurodevelopmental disorders. The expression pattern of \(Chd8\) was compared with \(Chd7\) and \(Chd2\). As these genes tend to be widely expressed during early development, we focused on later embryonic stages to identify novel expression sites during organogenesis. We report novel expression sites for all three genes during development, with examples of overlapping, complementary and distinct expression patterns.
Material and Methods

Animals

Timed-mated CD1 embryos and pups were produced in our in-house facility. Noon on the day a vaginal plug was detected was designated as embryonic day 0.5 (E0.5). The day of birth was designated as postnatal day (P)0. All experimental procedures were approved by the institutional Local Ethical Review Panel and the UK Home Office.

Primer design and probe synthesis

Primers were designed to amplify a 455 bp fragment of exon 37 of Chd8 from mouse genomic DNA: forward 5’-TCTCTGCTTTTATGCGGTTTG-3’; reverse 5’-CACCTCCTGAAGTCTTGGTTC-3’ with T7 recognition sequence added to the reverse primers in a PCR reaction. The resulting DNA template was used for the synthesis of digoxigenin (DIG)-labelled antisense or sense mRNA probes. A Chd7 probe template was made with primer pairs that amplify a 222 bp fragment of Chd7 exon 3 from mouse genomic DNA: forward 5’-TTGGTAAAGATGACTTCCCTGGTG-3’; reverse 5’-GTTTTGGCGTGACAGTTTTTGC-3’. A Chd2 625bp probe template was amplified from mouse brain cDNA using primer pairs: forward 5’-AGAAGAGCGTCCTCACAAGACTG-3’; reverse 5’-TTTTTCCTCAGGGTCCACAGG-3’.

Sample preparation

Embryos and brains were dissected in ice-cold diethylpyrocarbonate-treated phosphate buffered saline (DEPC PBS) and fixed in 4% paraformaldehyde (PFA) overnight. After several washes in DEPC PBS, embryos or brains were placed in cassettes immersed in 70% ethanol. The samples were processed in a Leica ASP300 tissue processor following a standard protocol. The processed samples were embedded in wax, sectioned sagittally at 10 µm using a Leica RM2145 microtome, placed on Superfrost Plus slides and left to dry at 42°C for 48 hours.
In situ hybridisation

E12.5, E14.5, P0, P7 and P20 sagittal sections on slides were deparaffinised in Xylene and rehydrated in decreasing series of ethanol concentrations. This was followed by DEPC PBS washes. Proteinase K (50 µg/ml in DEPC PBS) was added and sections were incubated for 10 minutes at 37 °C.

The slides were then washed in DEPC PBS, refixed in 4% PFA for 10 minutes and washed again in DEPC PBS. Sections were acetylated (acetic anhydride, 0.1M Triethanolamine, DEPC water at pH 7.5) for 10 minutes after which they were again washed in DEPC PBS thrice. Sections were dehydrated in 70% ethanol (5 minutes) and 95% ethanol (a few seconds) and left to air dry for a few minutes. 300 µl probe-hybridisation mix (2 µl of probe per ml hybridisation solution) (50% Dextran Sulfate, 50% Formamide, 1% Denhardts solution, 0.3M NaCl (sodium chloride), 20mM Tris-HCl (pH8), 10mM NaPO₄ (sodium phosphate), 5mM EDTA (Ethylenediaminetetraacetic acid), 250µg/ml Yeast tRNA, 1% sarcosyl, sterile water) pre-heated to 80°C were added to each slide and covered with parafilm. The slides were then arranged in a humid chamber (50% formamide/water) and incubated overnight at 65°C.

The following day the slides were washed in high stringency (HIS) (formamide, 0.1% SSC (saline-sodium citrate), sterile distilled water) wash for 30 minutes at 65°C followed by RNase buffer (0.5M NaCl, 10mM Tris-HCl pH 7.5, 5mM EDTA, distilled water) at 37 °C for 10 minutes (3x). Slides were treated with RNase buffer with 20 µg/ml RNase A at 37°C for 30 minutes followed by a single wash in RNase buffer at 37°C for 15 minutes. The slides were again washed twice in HIS at 65°C for 20 minutes each. 2x SSC and 0.1x SSC washes for 15 minutes were performed twice followed by PBT (PBS, 0.1% Tween 20) washes at room temperature. Sections were blocked with 10% heat inactivated goat serum in PBT for one hour at room temperature before a 3-hour incubation in alkaline phosphatase coupled with anti-dioxygenin antibody (1:500 dilution, Roche) and 1% heat-inactivated goat serum in PBT. At the end of incubation, slides were washed four times with PBT for 15 minutes each at room temperature followed by freshly prepared NTMT buffer (5M NaCl, 1M Tris-HCl at pH 9.5, 1M
MgCl₂, 0.1% Tween-20, sterile distilled water and 0.5 mg/ml levamisole) twice at room temperature. Finally, the slides were incubated in darkness in BM purple (Roche) and 0.5 mg/ml levamisole at room temperature overnight.

When signal appeared on sections, the reaction was stopped by washing in PBS at room temperature for 5 minutes. Slides were dehydrated with an increasing series of ethanol washes followed by Xylene before being mounted with Di-N-Butyle Phthalate in Xylene (DPX) and left to air dry.
Results

**Chd2, Chd7 and Chd8 gene expression in mouse embryos at E12.5 and E14.5.**

At E12.5 *Chd7* and *Chd8* expression was apparent throughout the neuroepithelium of the developing central nervous system (CNS) (Figure 1A, B). *Chd8* transcript signals were observed throughout the ventricular and subventricular regions of the neocortex and in the hindbrain (Figure 1Aa, Ab), including the cerebellum where expression was evident in the ventricular zone (VZ), rhombic lip (RL) and the isthmus (Figure 1Aa). Both VZ and RL are germinal centres where progenitor cells are born that later migrate and populate the cerebellum (White and Sillitoe, 2012). Notably, *Chd8* expression could also be observed at the lower rhombic lip and floor plate region of the hindbrain, extending to the spinal cord and dorsal root ganglia (Figure 1A, Supplementary Figure 1A). *Chd8* expression can be observed throughout the neural tube with no evident mediolateral nor dorsoventral gradient (Supplementary Figure 1A-D). Other regions of interest showing high *Chd8* expression included the diencephalon and areas adjacent to the hypothalamus and pituitary gland (Figure 1A). *Chd8* expression was observed throughout the craniofacial region including the tongue and olfactory epithelium (Figure 1A). Elsewhere, other organs of the embryo also showed substantial *Chd8* expression with signals present in the intersomitic regions, lungs, gut, genital tubercle and tail (Figure 1A).

As with *Chd8*, *Chd7* mRNA transcripts were observed throughout the embryo (Figure 1B). Expression was found in the ventricular region of the developing brain and spinal cord. *Chd7* mRNA transcripts were present in both the ventricular and subventricular zones of the neocortex (Figure 1Bb). In the hindbrain, *Chd7* was expressed in all regions including the upper rhombic lip of the cerebellum, the lower rhombic lip and floor plate (Figure 1Ba). *Chd7* expression was also observed in the diencephalon and the pituitary (Figure 1B). Within the neural tube expression was present in both cranial and caudal poles (Supplementary Figure 1E, F). Additionally, in transverse sections *Chd7* at this stage was noted to be enriched in the ventricular zone and displayed a
ventral to dorsal gradient within the developing spinal cord (Supplementary Figure 1G, H). Extensive expression was also observed outside the CNS. In the head region, diffuse Chd7 expression was present in the tongue. Other organs with expression included the dorsal root ganglia, intersomitic regions, gut, lungs, and the tail (Figure 1B).

At E12.5, Chd2 mRNA transcript signals could be found in many tissues in the developing mouse (Figure 1C), differentiated from background by use of a sense control (Supplementary Figure 2). Diffuse Chd2 expression was observed within the brain (Figure 1Ca, Cb), intersomitic regions and the spinal cord. Despite this increased signal density in brain tissue, the level of expression compared to other regions was low, suggesting that, at this stage, Chd2 is expressed ubiquitously at low levels throughout the embryo.

As several tissues outside of the CNS expressed both Chd7 and Chd8 strongly, these were compared directly at higher power. Sites of expression included the cochlea, lungs, eyes and kidneys (Figure 2A-D, F-I). For both, distinct expression levels were observed at the vestibulocochlear ganglion and cochlear epithelium in the ear (Figure 2A, F). In the kidney, expression levels were high in the mesenchyme and metanephric tubule epithelium (Figure 2B, G) whereas in the lung, expression was observed in the pulmonary epithelium (Figure 2C, H). Both transcripts were also observed in the neural retina/optic cup and retinal pigmented epithelium of the eyes, with Chd8 transcripts present widely throughout the surrounding mesenchyme and craniofacial tissues (Figure 2D, I). Interestingly, Chd8 also showed high expression in the incisor primordium, where no Chd7 expression was seen (Figure 2E).

In E14.5 embryos, several sites of prominent Chd8 expression could be seen (Figure 3A). In the head, abundant Chd8 transcripts were observed in the forebrain, midbrain, rhombic lip and ventricular zone of the cerebellum (Figure 3Aa). In the neocortex, significant expression was revealed in the ventricular, subventricular and mantle zones (Figure 3Ab). Prominent expression was also seen in the basal forebrain, including the ganglionic eminences, suggesting a role for Chd8 in the generation of GABA-ergic...
interneurons (Figure 3A). Diffuse or low Chd8 expression was observed in the
diencephalon and midbrain region. Extending from the hindbrain region, the spinal cord
also showed low expression. Elsewhere in the head, expression was seen in the olfactory
epithelium, the tongue and the ventral incisor. Other organs continued to show Chd8
expression as at E12.5, including the lungs, gut and kidneys. In addition, at E14.5, Chd8
transcripts were detected within the heart, thyroid, thymus, liver, gastric epithelium,
trigeminal ganglion and digits of the hind limb (Figure 3A).

Comparable to its expression at E12.5, high levels of Chd7 mRNA transcripts were
present most prominently in the ventricular region of the neocortex (Figure 3Bb) in
accordance with previous expression analyses (Engelen et al, 2011). Signals were also
observed in the midbrain region extending to the hindbrain (Figure 3B). Within the
cerebellum, significant Chd7 signals were observed at the rhombic lip and ventricular
zone of the fourth ventricle (Figure 3Ba). Widespread Chd7 expression was also present
in the diencephalon (Figure 3B). Extending from the hindbrain, the spinal cord showed
widespread Chd7 signal. In the oral region, the tongue and incisor primordium showed
Chd7 expression. Note that its expression in the tooth appears to occur later in
development, at E14.5, than its family member Chd8 (Figure 2J). Other organs such as
the lungs, thymus, heart, kidneys and liver, which showed significant Chd8 expression,
also displayed Chd7 expression (Figure 3B).

Chd2 expression at E14.5 was still low and widespread but was markedly elevated in
certain regions compared to E12.5 (Figure 3C). Strong signals were detected in the
neocortex (Figure 3Cb) and rhombic lip of the cerebellum (Figure 3Ca), enriched in the
ventricular zone of the cerebellum. In the craniofacial region the tongue, incisor
primordium and olfactory epithelium all stained for Chd2. Specific expression signals
outside of the head were noted in the kidney, liver, thymus, lung, thyroid, gut, digits of
the hindlimb and myogenic tissue (Figure 3C).

Much like at E12.5, both Chd8 and Chd7 transcripts could be detected in the kidneys,
lungs and eyes (Figure 3Ac-Ae, Bc-Be). Additionally, however a strong Chd2 signal
could also be detected in these tissues at this stage (Figure 3Cc-Ce). mRNA transcripts of all three genes were detected at the condensing mesenchyme of the kidney (Figure 3Ac, Be, Ce), epithelium of the lung (Figure, 3Ad, Bd, Cd) and neural retina, optic cup and lens of the eyes, with particularly strong expression of Chd7 seen in the retina (Figure, 3Ac, Bc, Cc). Notably, a Chd2 signal was also detected in the anatomical space containing the optic nerve and its surrounding structures at this stage (Figure 3Cc).

Distinct Chd2, Chd7 and Chd8 expression patterns in the postnatal mouse brain

In order to define the domains of Chd8 expression in the postnatal brain, in situ hybridisation on brain sections at P0 were carried out. At this stage, widespread expression of Chd8 was observed (Figure 4A, A’), in agreement with previous studies suggesting that Chd8 expression peaks during mid-gestation in the embryo (Bernier et al, 2014; Platt et al, 2017). Closer examination revealed expression throughout the cerebellum (Figure 4Aa) and a slight enrichment of Chd8 expression towards the outer neocortex (Figure 4Ab). Other Chd8-expressing regions of interest include the hippocampus, hypothalamus and olfactory bulb (Figure 4A, A’).

At this stage, a comparable widespread pattern of expression was seen for Chd7 (Figure 4B, B’, C, C’) with Chd7 exhibiting particularly strong expression in the cerebellum and pons (Figure 4Ba, Ca). Chd7 was highly expressed within the cerebellum in contrast to Chd2 and Chd8 for which moderately strong and more diffuse expression was seen (Figure 4Aa-Ca). Chd2 transcripts were enriched in the outer neocortex, hypothalamic area, superior olivary complex and basal pons (Figure 4C).

The expression patterns of these genes in the P7 brain were similarly widespread with continued expression in the cerebellum, neocortex and hippocampus (Figure 5A-C, A’-C’). Interestingly, all three genes appear to be expressed within the rostral migratory
stream (RMS) suggesting a role for the CHD family in coordinating the formation of
the infant olfactory system. High power images demonstrated prominent expression of
all three genes in the cerebellum (Figure 5Aa-Ca), the dentate gyrus (DG) and cornu
ammonis 1-3 (CA1-3) of the hippocampus (Figure 5Ab-Cb) and neocortex, enriched in
layers II-III of the neocortex (Figure 5Ac-Cc). This cortical distribution is particularly
marked for both Chd7 and Chd8 where a distinct band of high signal density can be
appreciated. Much like in the P0 brain, Chd7 was most strongly expressed in the
cerebellum.

At P20, Chd8 and Chd2 expression was prominent in the cerebellum, neocortex,
hippocampus, RMS and olfactory bulb (Figure 6A, A’, C, C’). Chd7 was most prominent
in the cerebellum, with low expression in the hippocampus, RMS and olfactory bulb
(Figure 6B, B’, Bc). All three genes were expressed in the maturing granule cell layer
(GCL) of the cerebellum (Figure 6Aa-Ca) and the DG and CA1-3 of the hippocampus
(Figure 6Ab-Cb). Chd2 and Chd7 expression in the hippocampus was much lower and
more diffuse compared to the prominent expression of Chd8 (Figure 6Ab-Cb). Clear
expression of Chd2 and Chd8 was noted in the neocortex, whilst Chd7 expression was
very low in comparison (Figure 6Ac-Cc).

**Discussion**

The results of the current study demonstrate that all three genes are widely expressed
and show little evidence of restricted temporal and spatial expression patterns during
embryonic development. Although expression seemingly occurs in many different
tissues in-utero it can be noted that neurological tissue in particular expresses these
members of the CHD family at a high level; an observation that is not wholly
unsurprising considering the phenotypic manifestations of mutations of these genes.

**CHD gene expression in the embryo**
Chd8 is widely expressed in embryonic stages E12.5 and E14.5, consistent with a continued role for CHD8 during early stages of development, after E7.5 when Chd8−/− mouse embryos were demonstrated to die due to apoptosis (Nishiyama et al, 2004). Recent work also implicated a role for CHD8 in suppressing p53 and the transactivation of genes under p53 control by preventing the process of apoptosis (Nishiyama et al, 2009). This could explain the early embryonic lethality observed. Moreover, the suggested role of CHD8 in transcription and elongation together with its role in controlling the expression of CCNE2 and TYMS which are involved in the G1/S phase of cell cycle reinforce its possible role in normal gene regulation and cell proliferation respectively (Rodriguez-Paredes et al, 2009), hence normal development.

Similar to Chd8, the widespread Chd2 and Chd7 expression suggests they also have important roles in early developmental processes and organogenesis. These data are consistent with the evidence that neither Chd2 nor Chd7 homozygotes thrive past early development (Bosman et al, 2005; Hurd et al, 2007; Marfella et al, 2006). The CHD7 gene is the dominant cause of CHARGE syndrome which is characterised by defects in the eye, brain, ear, heart and genitalia; areas in which we observed high levels of Chd7 expression (Janssen et al, 2012; Vissers et al, 2004). There are also reports of scoliosis caused by CHD7 mutations (Gao et al, 2007) which might relate to the expression we observed in the inter-somitic mesoderm. FAM124B was reported to be a component of a CHD7 and CHD8-containing complex (Batsukh et al, 2012) suggesting that this multiprotein complex could be functional in cells where Chd7 and Chd8 are co-expressed. Whereas CHD7 mutations are clearly linked to multi-organ defects in the context of CHARGE syndrome (Gao et al, 2007; Janssen et al, 2012; Patten et al, 2012; Van de Laar et al, 2007; Vissers et al, 2004), a clear role for CHD8 in organogenesis has not been reported. Here, however, we show that Chd8 is expressed in many developing organs including the lumen of stomach and midgut; an observation which may explicate the gastrointestinal complications associated with CHD8 mutations in ASD patients (Bernier et al, 2014).

In the case of Chd2, heterozygous mice most notably display an array of gross kidney abnormalities, which might pertain to the high levels of expression of this gene we
observed in the developing kidney (Marfella et al, 2008). Despite this association, the absence of reported renal dysgenesis in humans harbouring CHD2 mutations might indicate divergent functions for this gene in the human kidney, or a degree of functional redundancy with other CHD genes. Notably, at E14.5 the Chd2 expression pattern was markedly similar to Chd8 and indeed, several regions of the embryo at this stage expressed these two genes in exclusion of Chd7, suggesting the possibility that they may serve similar functions. Some such regions include the dorsal hindlimb, thyroid, gut and olfactory epithelium.

CHD genes in brain development

CHD2 and CHD8 mutations share a well-established link with ASD, a disorder that is widely regarded to be caused by aberrant neurodevelopment (Lebrun et al, 2017; O’Roak et al, 2012; Neale et al, 2012; Sanders et al, 2012). Our study demonstrates high levels of both Chd2 and Chd8 expression in the developing brain, especially during embryonic development. Additionally, preserved expression of both was revealed in key areas of the perinatal (P0) and postnatal brain (P7 and P20) including the cerebellum, hippocampus and neocortex – regions of the brain that are implicated in ASD (Allen, 2005; de Anda et al, 2012; Donovan & Basson, 2017; Riedel and Micheau, 2001). Within the neocortex expression of Chd2 and Chd8 appears to be particularly prominent within the outer layers, distinctly layers II-III of the postnatal brain, areas in which high numbers of other ASD risk genes are also enriched (Parikshak et al, 2013).

Taken together, and bolstered by evidence of aberrant neurodevelopmental phenotypes associated with mutants of these genes (Allen et al, 2013; Chérnier et al, 2014; Gompers et al, 2017; Katayama et al, 2016; Lebrun et al, 2017; O’Roak et al, 2014; Pinto et al, 2016; Platt et al, 2017; Suetterlin et al, 2018), our data suggest that Chd2 and Chd8 are expressed in a spatiotemporally appropriate way such that impairment in their expression might precipitate some of the neurological changes seen in patients with ASD. With both genes expressed in the SGZ of the hippocampus our data further support the notion that CHD2 and CHD8 might regulate neurogenesis (Shen et al, 2015; Durak
et al, 2016), akin to the reported role of their counterpart CHD7 (Feng et al, 2013; Jones et al, 2015).

In addition to its role in adult neurogenesis, the diverse, temporally distinct functions of CHD7 during cerebellar development (Yu et al, 2013; Whittaker et al, 2017a; Whittaker et al, 2017b; Donovan et al, 2017), are consistent with its pronounced expression in the postnatal cerebellum. In view of the role of CHD7 in neurodevelopment our study supports the notion that its mutation might account for the cerebellar hypoplasia associated with CHARGE syndrome. Furthermore, its expression in the olfactory bulb and RMS throughout postnatal development further bolsters the link between Kallmann syndrome, characterised by anosmia and hypogonadism, and CHD7 mutation (Jongmans et al, 2009).

Finally, the reported expression of Chd2 in the postnatal hippocampus invites a potential link between the dysfunction and deficiency of hippocampal interneurons documented in epileptic encephalopathies, temporal lobe epilepsy and seizures associated with ASD and its proposed role in interneuron development (Fyre et al, 2016; Lado et al, 2013; Liu et al, 2014; Meganathan et al, 2017). Furthermore, Chd2 expression in the eye and related structures during early development might also pertain to the association of CHD2 mutation with photosensitivity in epilepsy (Carvill et al, 2013; Galizia et al, 2015; Lund et al, 2014; Suls et al, 2013).

In conclusion, in addition to their established roles in early brain development, our expression analyses also implicate Chd2 and Chd8, alongside Chd7, in organogenesis. Our data also implicate all three genes in the process of postnatal neurogenesis due to their expression in the neurogenic niches of the adult brain. Additional studies will be necessary to further define the function of these genes in these developmental processes. The gene expression data reported here will provide invaluable information and reference points to guide these future studies.
Acknowledgements
This work was supported by an Anatomical Society Undergraduate Summer Vacation Scholarship to CO.

References


Pinto AM, Bianciardi L, Mencarelli MA, et al. (2016) Exome sequencing analysis in a pair of monozygotic twins re-evaluates the genetics behind their intellectual disability and reveals a CHD2 mutation. Brain Dev, 38, 590-596.


Figure legends

Figure 1. Distinct Chd8, Chd7 and Chd2 expression patterns at E12.5.

In situ hybridisation on sagittal sections of mouse embryos at developmental stage E12.5 using antisense riboprobes to detect Chd8, Chd7 and Chd2 mRNA, anterior to the right (A-C). Gene expression is indicated by purple/blue staining. Note the widespread Chd8 expression in most embryonic tissues (A), the high, localized expression of Chd7, specifically in the developing nervous system (B), and very low, widespread expression of Chd2 (C). High magnification images of the developing cerebellum (Aa-Ca) demonstrate the presence of Chd8 (Aa) and Chd7 (Ba) transcripts throughout the neuroepithelium, with little Chd2 expression evident (Ca). High magnification images through the neocortex show widespread Chd8 expression (Ab), note that Chd7 expression tends to be higher on the ventricular side (Bb) and that there is little discernible Chd2 expression (Cb). Other regions with relatively strong signals were the nasal epithelium, tail, genital tubercle, intersomitic mesoderm, spinal cord, mid brain, diencephalon, tongue and pituitary. Scale bars represent 100 µm.

Cb = cerebellum; Di = diencephalon; Drg = dorsal root ganglia; FP = floor plate; Gt = genital tubercle; Gu = gut; H = heart; Is = isthmus; Iso = intersomitic mesoderm; Lu = lungs; LRL = lower rhombic lip; MB = midbrain; MZ = molecular zone; NC = neocortex; Pi = pituitary; Sc = spinal cord; SVZ = subventricular zone; Ta = tail; To = tongue; URL = upper rhombic lip; VZ = ventricular zone.

Figure 2. Chd7 and Chd8 are expressed in multiple organs at E12.5.
**In situ** hybridisation images of *Chd8* (A-E) and *Chd7* (F-I) transcripts around the cochlea of the inner ear (A, F), kidney (B, G), lung (C, H) eye (D, I) and tooth (E, J). Scale bars represent 100 µm.

*C = cornea; CD = cochlear duct; CVG = cochlea-vestibular ganglia; CM = condensing mesenchyme; LE = lung epithelium; LN = lens; MT = metanephric tubule; NR = neuroretina; PI = primordium of incisor; PO = pre-optic cup; RPE = retinal pigmented epithelium; SB = segmental bronchus.*

**Figure 3. Distinct nervous system and organ-specific expression patterns of Chd8, Chd7 and Chd2 in E14.5 mouse embryos.**

*In situ* hybridisation on sagittal sections of E14.5 mouse embryos (A-C), anterior to the right. Note distinct *Chd8*, *Chd7* and *Chd2* expression patterns throughout the embryos with notably higher level in the developing nervous system. Beyond the nervous system, other notable regions of expression included various organs and glands, for example the thymus and thyroid, heart and kidneys. High magnification images (Aa-Ce) revealed specific expression patterns in the cerebellum (Aa-Ca), Neocortex (Ab-Cb), Eye (Ac-Cc), Lung (Ad-Cd) and kidney (Ae-Ce). Scale bars represent 100 µm.

B = bronchus; C = cornea; Cb = cerebellum; CD = collecting duct; CM = condensing mesenchyme; CP = choroid plexus; C-PL = cortical plate; Di = diencephalon; Dh = digit of hindlimb; GE = gastric epithelium; GEm = ganglionic eminence; Gu = gut; H = heart; K = kidney; LC = lens capsule; LE = lung epithelium; Li = liver; LN = lens; Lu = lung; Mb = mid brain roof plate; MZ = marginal zone; NC = neocortex; NR = neural retina; OE = olfactory epithelium; ON = optic nerve and surrounding structures; PO = pre-optic cup; RL = rhombic lip; RPE = retinal pigmented epithelium; Sc = spinal cord; T = thyroid; To = tongue; Ta = tail; Th = thymus; TG = trigeminal ganglion; vI = ventral incisor; VZ = ventricular zone.
Figure 4. Comparative Chd8, Chd7 and Chd2 expression patterns in the newborn mouse brain.

Sagittal sections through newborn mouse brain (anterior to the right), hybridised with antisense RNA probes to detect Chd8 (A, A'), Chd7 (B, B') and Chd2 (C, C') transcripts in blue. Note wide-spread expression of Chd8, highly localised Chd7 expression in the cerebellum and pons, and Chd2 in the neocortex, midbrain and cerebellum. High magnification views of the cerebellum (Aa-Ca) and neocortex (Ab-Cb) are shown. Scale bars represent 100 µm.

Cb = cerebellum; EGL = external granule cell layer; HC = hippocampus; Hy = hypothalamus; I = cortical layer I; II-III = cortical layers II-III; IC = inferior colliculus; IGL = internal granule cell layer; Me = medulla; NC = neocortex; OB = olfactory bulb; Pn = pons; SC = superior colliculus; SOC = superior olivary complex.

Figure 5. Chd8, Chd7 and Chd2 are expressed in the early postnatal cerebellum, hippocampus, neocortex and rostral migratory stream.

Sagittal sections through postnatal day 7 (P7) mouse brain (anterior to the right), hybridised with antisense RNA probes to detect Chd8 (A, A'), Chd7 (B, B') and Chd2 (C, C') transcripts, visualised in blue. Higher magnification images to visualise specific expression domains in the cerebellum (Aa-Ac), hippocampus (Ba-Bc), and neocortex (Ca-Cc) are shown. Scale bars represent 100 µm.

CA1-3 = cornu ammonis 1-3; Cb = cerebellum; DG = dentate gyrus; EGL = external granule cell layer; GL = glomerular layer; HC = hippocampus; I = cortical layer I; II-III = cortical layers II-III; IGL = internal granule cell layer; IPL = internal plexiform layer; ML = molecular layer; NC = neocortex; OB = olfactory bulb; RMS = rostral migratory stream; SGZ = subgranular zone; WM = white matter.

Figure 6. Comparison of Chd8, Chd7 and Chd2 expression patterns in the P20 mouse brain.
Sagittal sections through P20 mouse brain (anterior to the right), hybridised with antisense RNA probes to detect \textit{Chd8} (A, A'), \textit{Chd7} (B, B') and \textit{Chd2} (C, C') transcripts, visualised in blue. Note high expression of all three genes in the cerebellum, with widespread \textit{Chd8} and \textit{Chd2} expression remaining in the neocortex. High magnification images of the cerebellum (Aa-Ca); hippocampus (Ab-Cb) and neocortex (Ac-Cc) are shown. Scale bars represent 100 µm.

CA1-3 = cornu ammonis 1-3; Cb = cerebellum; DG = dentate gyrus; GCL = granule cell layer; HC = hippocampus; I = cortical layer I; II-III = cortical layers II-III; ML = molecular layer; NC = neocortex; OB = olfactory bulb; RMS = rostral migratory stream; SGZ = subgranular zone; WM, = white matter.

Supplementary Figure 1. Distinct \textit{Chd8} and \textit{Chd7} expression patterns within the neural tube at E12.5.

\textit{In situ} hybridisation on sagittal (anterior to the right) and transverse sections of mouse embryos at developmental stage E12.5 using antisense riboprobes to detect \textit{Chd8} and \textit{Chd7} mRNA (A-H). Gene expression is indicated by purple/blue staining. Note that both \textit{Chd8} and \textit{Chd7} are expressed throughout the length of the neural tube (A, B, E, F). Whilst \textit{Chd8} displays no mediolateral or dorsoventral gradient in transverse sections \textit{Chd7} shows distinct enrichment in the ventricular zone of the developing CNS and a ventral to dorsal gradient within the spinal cord.

Drg = dorsal root ganglia; Iso = intersomitic region; LGE = lateral ganglionic eminence; MGE = medial ganglionic eminence; No = notochord; NT = neural tube; SE = surface ectoderm.

Supplementary Figure 2. Sense control sections at E12.5.

\textit{In situ} hybridisation on sagittal (anterior to the right) sections of mouse embryos at developmental stage E12.5 using sense riboprobes to \textit{Chd8}, \textit{Chd7} and \textit{Chd2} mRNA. Note that for all three genes there is little to no hybridisation or staining using the sense riboprobe in contrast to what is seen when using the anti-sense probe.
Figure 1

A

Chd8

B

Chd7

C

Chd2

Cerebellum

(Aa)

URL

IS

VZ

Ca

C

Neocortex

(AB)

VZ+SVZ

(MZ)

B

VZ+SVZ

(MZ)

Bb

Cb

Figure 1